Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

15.11.24	Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria (RTTNews)
06.11.24	Regeneron: EC Approves Dupixent For Young Children With EoE (RTTNews)
29.10.24	Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall (RTTNews)
25.10.24	Sanofi Q3 Profit Rises - Quick Facts (RTTNews)
21.10.24	Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R (RTTNews)
17.10.24	PAI Partners Raises Offer For Sanofi's Consumer Health Biz Opella: Reports (RTTNews)
16.10.24	FDA Updates Sanofi's FLUBLOK Vaccine Label With New Safety Data For Pregnant Individuals (RTTNews)
09.10.24	Sanofi : Beyfortus Data Reinforce Effectiveness Against RSV Disease & Hospitalization In Infants (RTTNews)
27.09.24	Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment (RTTNews)
27.09.24	Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease (RTTNews)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (EN, Sanofi-Aventis)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (EN, Sanofi-Aventis)
16.09.24	Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts (RTTNews)
12.09.24	Sanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare Cancers (RTTNews)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (EN, Sanofi-Aventis)
11.09.24	Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints (RTTNews)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (EN, Sanofi-Aventis)
10.09.24	Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies (EN, Sanofi-Aventis)
02.09.24	Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS (RTTNews)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (EN, Sanofi-Aventis)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
26.08.24	Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases (EN, Sanofi-Aventis)
08.08.24	Sanofi : Sarclisa Induction Treatment Improves PFS In Transplant-Eligible Myeloma Patients (RTTNews)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (EN, Sanofi-Aventis)
25.07.24	Press Release: Online availability of Sanofi’s half-year financial report for 2024 (EN, Sanofi-Aventis)
25.07.24	Sanofi Q2 Profit Down, Sales Rise; Lifts FY24 Business EPS View (RTTNews)
25.07.24	Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded (EN, Sanofi-Aventis)
18.07.24	Sanofi : ALTUVIIIO XTEND-Kids Phase 3 Data Transforming Severe Hemophilia A Treatment For Children (RTTNews)
17.07.24	Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A (EN, Sanofi-Aventis)
03.07.24	Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients (RTTNews)
03.07.24	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (EN, Sanofi-Aventis)
28.06.24	Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS (EN, Sanofi-Aventis)
26.06.24	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (EN, Sanofi-Aventis)
25.06.24	Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy (EN, Sanofi-Aventis)
25.06.24	Press Release: Availability of the Q2 2024 Aide-mémoire (EN, Sanofi-Aventis)
21.06.24	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee (EN, Sanofi-Aventis)
21.06.24	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran (EN, Sanofi-Aventis)
20.06.24	Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa (RTTNews)
20.06.24	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa (EN, Sanofi-Aventis)
11.06.24	Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA (RTTNews)
03.06.24	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 (EN, Sanofi-Aventis)
01.06.24	Media Update: Sanofi update on Zantac litigation (EN, Sanofi-Aventis)
31.05.24	Sanofi Launches 2024 Employee Stock Purchase Plan - Quick Facts (RTTNews)
31.05.24	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan (EN, Sanofi-Aventis)
31.05.24	Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients (RTTNews)
31.05.24	Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month (RTTNews)
31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (EN, Sanofi-Aventis)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (EN, Sanofi-Aventis)
30.05.24	Press Release: Sanofi completes acquisition of Inhibrx, Inc. (EN, Sanofi-Aventis)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung
26.06.24		Sanofi-Aktie im Minus: Verkauf von Consumer Health steht offenbar in den Startlöchern - möglicher IPO